Bicycle Therapeutics plc
BCYC
$9.69
$0.060.62%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.76% | 48.60% | 75.74% | 168.47% | 86.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.76% | 48.60% | 75.74% | 168.47% | 86.52% |
| Cost of Revenue | -64.17% | 25.65% | 37.26% | 62.44% | 91.76% |
| Gross Profit | 86.81% | -20.42% | -28.08% | -42.56% | -92.89% |
| SG&A Expenses | 19.45% | 10.65% | 19.04% | 28.12% | 22.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.01% | 21.06% | 31.62% | 51.10% | 65.44% |
| Operating Income | -10.49% | -16.99% | -24.86% | -37.22% | -62.83% |
| Income Before Tax | 3.02% | -5.48% | -14.97% | -32.16% | -56.87% |
| Income Tax Expenses | -427.04% | -569.04% | 231.46% | 200.12% | 195.60% |
| Earnings from Continuing Operations | 6.44% | -2.93% | -18.13% | -35.38% | -60.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.44% | -2.93% | -18.13% | -35.38% | -60.28% |
| EBIT | -10.49% | -16.99% | -24.86% | -37.22% | -62.83% |
| EBITDA | -10.52% | -17.12% | -25.33% | -37.20% | -62.35% |
| EPS Basic | 43.93% | 34.10% | 18.59% | -6.77% | -35.03% |
| Normalized Basic EPS | 41.23% | 33.33% | 20.86% | -4.37% | -32.52% |
| EPS Diluted | 43.93% | 34.10% | 18.59% | -6.77% | -35.03% |
| Normalized Diluted EPS | 41.23% | 33.33% | 20.86% | -4.37% | -32.52% |
| Average Basic Shares Outstanding | 63.58% | 59.07% | 47.64% | 30.00% | 19.85% |
| Average Diluted Shares Outstanding | 63.58% | 59.07% | 47.64% | 30.00% | 19.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
